The absence of LC3A-II in non-alcoholic fatty liver disease (NAFLD) may result from inhibited lipidation of LC3A-I, preventing its conversion to LC3A-II. This evidence concerns the gene MAP1LC3A and metabolic dysfunction-associated steatotic liver disease.